This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
1
0
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
- BMO Capital analyst Evan Seigerman downgraded the rating for Biogen Inc. (NASDAQ:BIIB) from Outperform to Market Perform and lowered the price target from $230 to $164. Biogen shares closed at $147.39 on Thursday. See how other analysts view this stock.
- Telsey Advisory Group analyst Cristina Fernandez downgraded NIKE, Inc. (NYSE:NKE) from Outperform …
Full story available on Benzinga.com
Visited 1 times, 1 visit(s) today